Poniard Pharmaceuticals, Inc. (PARD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Poniard Pharmaceuticals, Inc. (PARD) with AI Score 48/100 (Weak). Poniard Pharmaceuticals, Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Poniard Pharmaceuticals, Inc. (PARD) Healthcare & Pipeline Overview
Poniard Pharmaceuticals, Inc., a biopharmaceutical company established in 1984, focuses on the development of Picoplatin, a platinum-based cancer therapy targeting various cancers, including small cell lung, colorectal, prostate, and ovarian cancers. The company has completed Phase III and Phase II trials, positioning it within the competitive oncology therapeutics market.
Investment Thesis
Poniard Pharmaceuticals, Inc. presents a speculative investment opportunity within the biotechnology sector, primarily driven by the potential of its lead drug candidate, Picoplatin. The company's past clinical trials, including the Phase III SPEAR trial, provide a foundation for future development, though previous trial results have not led to commercialization. Key value drivers include successful reformulation or repurposing of Picoplatin, securing partnerships for further development, and potential breakthroughs in cancer treatment. However, the company's limited financial resources, as indicated by its $0 market capitalization and negative ROE of -210.4%, pose significant risks. The high beta of -68.57 suggests extreme volatility. Investment hinges on the company's ability to attract funding and demonstrate clinical progress.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's current financial challenges and lack of investor confidence.
- Return on Equity (ROE) of -210.4% indicates significant losses and inefficient use of equity.
- Debt-to-Equity Ratio of 52.62 suggests a moderate level of financial leverage.
- Negative Free Cash Flow (FCF) of $-0.00B highlights the company's inability to generate positive cash flow from operations.
- Beta of -68.57 indicates an inverse correlation with the market, but also suggests high volatility and potential instability.
Competitors & Peers
Strengths
- Lead drug candidate, Picoplatin, with potential in multiple cancer indications.
- Completed Phase III SPEAR trial provides a foundation for further development.
- Established research and development capabilities.
- Focus on a specific therapeutic area (platinum-based cancer therapies).
Weaknesses
- Limited financial resources and negative free cash flow.
- Dependence on a single drug candidate.
- Past clinical trial results have not led to commercialization.
- Lack of strategic partnerships.
Catalysts
- Upcoming: Potential for securing partnerships to fund and accelerate the clinical development of Picoplatin.
- Upcoming: Results from ongoing research into new applications for Picoplatin in different cancer types.
- Ongoing: Continued efforts to develop an oral formulation of Picoplatin.
- Ongoing: Pursuit of orphan drug designation for Picoplatin in rare cancers.
- Ongoing: Exploration of combination therapies involving Picoplatin and other cancer treatments.
Risks
- Ongoing: Limited financial resources and negative free cash flow pose a significant threat to the company's operations.
- Potential: Dependence on a single drug candidate makes the company vulnerable to clinical trial failures or regulatory setbacks.
- Potential: Competition from larger pharmaceutical companies with more resources could hinder Poniard's growth.
- Potential: Regulatory hurdles and the risk of clinical trial failures could delay or prevent the commercialization of Picoplatin.
- Ongoing: Trading on the OTC Other tier carries higher risk and greater potential for volatility.
Growth Opportunities
- Repurposing Picoplatin for New Cancer Indications: Poniard could explore new applications for Picoplatin in different cancer types. The global oncology market is projected to reach $286.6 billion by 2030. Identifying a niche indication with unmet needs could provide a significant growth opportunity, potentially leading to accelerated clinical trials and market approval within 3-5 years.
- Developing Oral Formulation of Picoplatin: The Phase I study evaluating an oral formulation of Picoplatin presents a growth opportunity. Oral cancer drugs offer patient convenience and potentially improved compliance. Success in developing and commercializing an oral formulation could expand Picoplatin's market reach and provide a competitive advantage. Timeline for development and approval is estimated at 4-6 years.
- Strategic Partnerships for Clinical Development: Poniard could seek partnerships with larger pharmaceutical companies to fund and accelerate the clinical development of Picoplatin. Collaborations can provide access to resources, expertise, and established distribution networks. Securing a partnership within the next 1-2 years could significantly enhance Poniard's prospects.
- Focusing on Orphan Drug Designations: Targeting rare or orphan cancers with Picoplatin could provide regulatory and financial incentives, including market exclusivity and accelerated approval pathways. The orphan drug market is growing rapidly, offering a potential niche for Poniard. Pursuing orphan drug designation could lead to market entry within 3-4 years.
- Exploring Combination Therapies: Investigating the use of Picoplatin in combination with other cancer therapies, such as immunotherapies or targeted agents, could enhance its efficacy and broaden its applicability. Combination therapies are becoming increasingly common in oncology. Clinical trials evaluating combination regimens could yield positive results within 2-3 years.
Opportunities
- Repurposing Picoplatin for new cancer indications.
- Developing an oral formulation of Picoplatin.
- Securing strategic partnerships for clinical development.
- Targeting orphan drug designations.
Threats
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and the risk of clinical trial failures.
- Patent expiration and the emergence of generic competitors.
- Difficulty in securing funding and maintaining operations.
Competitive Advantages
- Patent protection for Picoplatin (if patents are still valid).
- Clinical data from completed Phase III and Phase II trials.
- Expertise in platinum-based cancer therapies.
- Established research and development infrastructure.
About PARD
Poniard Pharmaceuticals, Inc., founded in 1984, is a biopharmaceutical company headquartered in Seattle, Washington. Initially named NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals in 2006. The company is dedicated to the development and commercialization of innovative cancer therapeutics. Poniard's primary focus is Picoplatin, a novel platinum-based compound designed to treat a range of cancer indications. Picoplatin has been investigated for its potential in treating small cell lung cancer, colorectal cancer, prostate cancer, and ovarian cancer. Poniard has conducted several clinical trials to assess the efficacy and safety of Picoplatin. These include a pivotal Phase III SPEAR trial for second-line treatment of small cell lung cancer, Phase II trials evaluating Picoplatin as a first-line treatment for metastatic colorectal cancer and castration-resistant prostate cancer, and a Phase I study exploring an oral formulation of Picoplatin in solid tumors. The company's research and development efforts are centered on advancing Picoplatin through the clinical trial process to potentially bring new treatment options to cancer patients. Poniard operates within the highly competitive biotechnology sector, striving to make a meaningful impact in oncology therapeutics.
What They Do
- Develop and commercialize cancer therapeutics.
- Focus on platinum-based cancer therapy, Picoplatin.
- Conduct clinical trials to evaluate the safety and efficacy of Picoplatin.
- Target multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers.
- Explore different formulations of Picoplatin, including oral formulations.
- Seek strategic partnerships to advance clinical development.
Business Model
- Develop and patent novel cancer therapeutics.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval for commercialization.
- Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
Industry Context
Poniard Pharmaceuticals operates within the biotechnology industry, a sector characterized by high risk and high reward. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Competition is intense, with numerous companies, ranging from large pharmaceutical firms to smaller biotechs, vying for market share. Poniard's success depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate the clinical efficacy of Picoplatin. The company's focus on platinum-based therapies places it in a niche segment of the broader oncology market.
Key Customers
- Cancer patients suffering from small cell lung, colorectal, prostate, and ovarian cancers.
- Oncologists and other healthcare professionals who treat cancer patients.
- Hospitals and cancer centers that administer cancer therapies.
Financials
Chart & Info
Poniard Pharmaceuticals, Inc. (PARD) stock price: Price data unavailable
Latest News
No recent news available for PARD.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PARD.
Price Targets
Wall Street price target analysis for PARD.
MoonshotScore
What does this score mean?
The MoonshotScore rates PARD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
PARD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Poniard Pharmaceuticals may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier is generally associated with higher risk and greater potential for volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial reporting, making it difficult to assess the company's financial health.
- Low trading volume and liquidity, leading to wide bid-ask spreads and price volatility.
- Higher risk of fraud or manipulation compared to stocks listed on major exchanges.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1984.
- Focus on developing cancer therapeutics addresses a significant market need.
- Previous clinical trials (Phase III SPEAR trial) suggest some level of research and development activity.
- Company was previously listed as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006.
What Investors Ask About Poniard Pharmaceuticals, Inc. (PARD)
What does Poniard Pharmaceuticals, Inc. do?
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Its primary asset is Picoplatin, a platinum-based compound being investigated for the treatment of various cancers, including small cell lung, colorectal, prostate, and ovarian cancers. The company conducts clinical trials to evaluate the safety and efficacy of Picoplatin, with the goal of bringing new treatment options to cancer patients. Poniard operates within the competitive biotechnology sector, striving to make a meaningful impact in oncology therapeutics through targeted drug development.
What do analysts say about PARD stock?
Given that Poniard Pharmaceuticals trades on the OTC Other tier and has a market capitalization of $0.00B, formal analyst coverage is unlikely. Key valuation metrics, such as price-to-earnings ratio or price-to-sales ratio, are not applicable due to the company's lack of revenue and earnings. Growth considerations are primarily centered on the potential for Picoplatin to achieve clinical success and secure regulatory approval. However, the company's limited financial resources and high-risk profile warrant caution.
What are the main risks for PARD?
The main risks for Poniard Pharmaceuticals include its limited financial resources, dependence on a single drug candidate (Picoplatin), and the inherent challenges of drug development. Clinical trial failures, regulatory setbacks, and competition from larger pharmaceutical companies pose significant threats. Additionally, trading on the OTC Other tier carries higher risk due to limited liquidity, potential for manipulation, and lack of regulatory oversight. Investors should carefully consider these risks before investing in PARD.
What are the key factors to evaluate for PARD?
Poniard Pharmaceuticals, Inc. (PARD) currently holds an AI score of 48/100, indicating low score. Key strength: Lead drug candidate, Picoplatin, with potential in multiple cancer indications.. Primary risk to monitor: Ongoing: Limited financial resources and negative free cash flow pose a significant threat to the company's operations.. This is not financial advice.
How frequently does PARD data refresh on this page?
PARD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PARD's recent stock price performance?
Recent price movement in Poniard Pharmaceuticals, Inc. (PARD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Lead drug candidate, Picoplatin, with potential in multiple cancer indications.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PARD overvalued or undervalued right now?
Determining whether Poniard Pharmaceuticals, Inc. (PARD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PARD?
Before investing in Poniard Pharmaceuticals, Inc. (PARD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be incomplete or outdated.
- The company's financial situation is precarious, and its future is uncertain.
- Trading on the OTC Other tier carries significant risks.